![](/-/media/icons/2019/pharma/biomedtracker-icon.png?rev=fc7926a0385c4901b67c1887d9aac276)
Merck pays $50mm cash up front in new viral disease mRNA deal with Moderna; Agreement Cancelled
Executive Summary
Merck & Co. Inc. is entering the messenger-RNA space through a new deal with Moderna Therapeutics LLC aimed at turning out vaccines and passive immunity therapies against viral diseases.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Concluded
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice